Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

58 results about "Corneal limbus" patented technology

The corneal limbus is the border of the cornea and the sclera (the white of the eye). The limbus is a common site for the occurrence of corneal epithelial neoplasm. The limbus contains radially-oriented fibrovascular ridges known as the palisades of Vogt that may harbour a stem cell population. The palisades of Vogt are more common in the superior and inferior quadrants around the eye. Aniridia, a developmental anomaly of the iris, disrupts the normal barrier of the cornea to the conjunctival epithelial cells at the limbus.

Preparation method and application thereof of acellular conjunctiva matrix

The invention relates to a preparation method and application thereof of an acellular conjunctiva matrix used as a tissue engineering corneal scaffold material. The method comprises the following steps: removing cell components in a bulbar conjunctiva first; preparing the acellular conjunctiva matrix; and taking the acellular conjunctiva matrix as a tissue engineering corneal scaffold. A rabbit corneal epithelium or an endothelial cell can form a good cell single layer on the scaffold, can construct a tissue engineering corneal epithelium or endothelium, and can successfully transplant the tissue engineering corneal epithelium or endothelium onto rabbit animal model eyes. The degradation time of the built tissue engineering cornea is longer, rabbit eyes have no obvious immune reject reaction, and the therapeutic effects on the lack of corneal limbus stem cells or the decompensation of the corneal endothelial cell function are obvious. The method and the application thereof have the advantages of simple preparation method, good biocompatibility, low antigenicity, easy growth and proliferation of seed cells, slow degradation, extensive bulbar conjunctiva sources and wide application and development prospects; and the transparency can be maintained all the time in the training process and after transplantation.
Owner:SHANDONG EYE INST

Cornea metaphase preservation solution, and preparing and using methods thereof

InactiveCN103053511AImprove cloning abilityLess fusionDead animal preservationApoptosisTobramycin
The invention provides a cornea metaphase preservation solution, and preparing and using methods thereof. The cornea metaphase preservation solution is a cell culture minimum essential medium (MDM) with chondroitin sulfate, low molecular dextran, L-glutamine, dexamethasone, tobramycin, 2-hydroxyethyl and Y-27632 added. The preservation solution not only can keep activity and normal morphology of cornea endothelial cells, but also can enhance viability of corneal limbus epithelial cells and improve clone ability of corneal limbus stem cells. And especially, a medium to long term preservation effect is obvious, phenomena of deformation, conjugation and the like of endothelial cells of a control group cornea do not appear in long term preservation, endothelial morphology of the control group cornea is consistent with endothelial morphology of a cornea preserved for 4 days, and the endothelial cells of the control group cornea are still regular and few in cell conjugation phenomena. The preservation solution can effectively prevent cell apoptosis phenomena during the process of preserving isolated cornea materials, increases activity and clone forming ability of the corneal limbus stem cells, and enables the cornea to maintain a transparent feature in a long preservation time.
Owner:SHANDONG EYE INST

Method for preparing amniotic compound corneal limbus stem cell membrane

The invention relates to a method for preparing an amniotic compound corneal limbus stem cell membrane, which comprises the following steps of: firstly, preparing a sterile amniotic membrane with epithelium removed, placing the epithelial surface of the amniotic membrane downwards on an end face of a sleeve made of a poly propylene material, and covering an embedded culture transwell on the amniotic membrane of the sleeve to obtain an amniotic-membrane-embedded culture mold; placing the culture mold in holes in a 6-hole plate on which a mouse embryonic fibroblast cell feeder layer is spread; and finally, preparing a corneal limbus stem cell suspension by using a digestion method, inoculating the suspension on the epithelial surface of the amniotic membrane, inoculating 2.0-3.0*10<5> corneal limbus stem cells for each culture mold, and culturing the corneal limbus stem cells for 10 days to obtain the amniotic compound corneal limbus stem cell membrane. Compared with the traditional amniotic membrane spreading method and the latex ring amniotic membrane fixing method, the amniotic compound corneal limbus stem cell membrane prepared with the method has flat amniotic membrane culturing surface and uniform corneal limbus stem cell stratified layer and especially has the advantage of convenience for clinic application and difficulty in rapture of the amniotic membrane.
Owner:SHANDONG EYE INST

Decellularized corneal limbus protective liquid and preparation method of decellularized corneal limbus

The invention relates to the field of bioengineering medical materials, and discloses decellularized corneal limbus protective liquid and a preparation method of decellularized corneal limbus. The component of the decellularized corneal limbus protective liquid is a PBS buffer solution containing hyaluronic acid of 5 to 12 g/L, chondroitin sulfate of 5 to 20 g/L, low molecular dextran of 3 to 10 g/L and tobramycin of 2.5 to 5 mg/L. A fresh pig corneoscleral limbal matrix containing lamina elastica anterior is sealed in the decellularized corneal limbus protective liquid and cells are crushed through high hydrostatic pressure treatment; the corneal limbus of the crushed cells are put into the decellularized corneal limbus protective liquid added with a detergent and nuclease to perform oscillation decellularized treatment; and the decellularized corneal limbus is put into the decellularized corneal limbus protective liquid to be rinsed to finish preparation. The decellularized corneal limbus obtained by the method is complete in decellularization, minimally reduces damage to the corneal limbus structure, has high biocompatibility and is favorable for autologous cell proliferation and crawling.
Owner:健诺维(成都)生物科技有限公司

Recombinant vector, fibroin film modified by transgenic marrow stromal cells and application thereof

InactiveCN102242148ASenses disorderMicroorganism based processesCornea layerCorneal layer
The invention relates to the biology field, and concretely discloses a recombinant plasmid pAdTrack-CMV-VEGF165-PolyA-promoter-Ang of VEGF165 and Ang-1 as well as a recombinant plasmid pAdTrack-CMV-VEGF165-IRES- Ang-1 of VEGF165 and Ang-1, wherein the preservation numbers are CCTCC No: M 2010221, CCTCC NO: M 2010220. The invention also discloses a homologous recombination of the plasmid and adenovirus and a recombinant adenovirus incased and generated from a QBI-293A cell. The invention also provides a fibroin film modified by transgenic marrow stromal cells. Rabbit corneal limbus injected with the recombination adenovirus provided in the invention is capable of successfully inducing the formation of corneal neovascularization; after the fibroin film modified by transgenic cells is implanted in a rabbit cornea layer, the neovascularization can be grown in a cornea of a fibroin film implanted area and the density of blood vessels is obviously increased, therefore, VEGF165, Ang-1, CD34 can be successfully expressed in a rabbit cornea layer. Wound repairing experiments of rats prove that the fibroin film modified by transgenic marrow stromal cells of the invention is capable of promoting the blood vessel generation of the wound organization and repairing wound, so that the recombinant adenovirus and the fibroin film modified by transgenic marrow stromal cells of the invention have medical application value.
Owner:SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products